Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1615 1618
This examiner grants 63% of resolved cases
| App # | Title | Status | Assignee |
|---|---|---|---|
| 19221432 | COMPOSITIONS AND METHODS OF USE FOR MODIFIED RELEASE MINOXIDIL | Final Rejection | Veradermics, Incorporated |
| 19308925 | AMORPHOUS KINASE INHIBITOR FORMULATIONS AND METHODS OF USE THEREOF | Final Rejection | Deciphera Pharmaceuticals, LLC |
| 18042930 | NICLOSAMIDE PARTICLES AND USES THEREOF | Final Rejection | CRITITECH, INC. |
| 19270315 | PHARMACEUTICAL COMPOSITIONS COMPRISING BUPROPION AND CYSTEINE | Final Rejection | ANTECIP BIOVENTURES II LLC |
| 18422155 | PERSONAL CARE PRODUCT CUSTOMIZED BY DISCRETE PARTICLES AND METHOD OF APPLY THEREOF | Non-Final OA | The Procter & Gamble Company |
| 19190529 | IMMEDIATE RELEASE MULTILAYER TABLET | Final Rejection | Alkermes Pharma Ireland Limited |
| 18008793 | ANATABINE POWDER COMPOSITIONS | Non-Final OA | PHILIP MORRIS PRODUCTS S.A. |
| 18413822 | PHARMACEUTICAL COMPOSITION, PHARMACEUTICAL DOSAGE FORM, PROCESS FOR THEIR PREPARATION, METHODS FOR TREATING AND USES THEREOF | Final Rejection | Boehringer Ingelheim International GmbH |
| 18284981 | METHOD FOR PREPARING MICROPARTICLES CONTAINING POORLY SOLUBLE DRUGS | Non-Final OA | INVENTAGE LAB INC. |
| 18010245 | FORMULATION COMPRISING DAPRODUSTAT | Non-Final OA | GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED |
| 18532735 | COMPOSITIONS FOR PRE-SURGICAL NUTRITIONAL SUPPLEMENTS | Non-Final OA | TM Nutrition LLC |
| 18019856 | SOLID ORAL COMPOSITION COMPRISING CARBAMATE COMPOUND, AND PREPARATION METHOD THEREFOR | Final Rejection | SK BIOPHARMACEUTICALS CO., LTD. |
| 17998863 | PHARMACEUTICAL COMPOSITION | Final Rejection | GLAXOSMITHKLINE CONSUMER HEALTHCARE HOLDINGS (US) LLC |
| 18001635 | Dispersible Tablet Formulations Comprising Dolutegravir | Final Rejection | ViiV Healthcare Company |
| 18001634 | Formulations | Final Rejection | ViiV Healthcare Company |
| 18359973 | FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS | Non-Final OA | XSPRAY PHARMA AB |
| 18064383 | FAST DISSOLVING PHARMACEUTICAL COMPOSITIONS | Final Rejection | XSPRAY PHARMA AB |
| 18273732 | STABLE EMULSIONS AND METHODS | Non-Final OA | Hemp Hunter Labs Inc. |
| 18043176 | PHARMACEUTICAL COMPOSITION COMPRISING IBRUTINIB | Final Rejection | Synthon B.V. |
| 18212671 | PROCESS FOR THE PREPARATION OF DRUG DELIVERY SYSTEMS HAVING A TESTOSTERONE COMPOUND PRESENT IN AN OUTER LAYER OR PART, AS WELL AS SUCH DRUG DELIVERY SYSTEMS | Non-Final OA | EB IP Hybritabs B.V. |
| 17998689 | COMPOSITIONS AND METHODS FOR HARDENING | Non-Final OA | SPI Pharma, Inc. |
| 17911040 | TABLET, MEDICINE, METHODS FOR PRODUCING THESE, AND KIT | Non-Final OA | Eisai R&D Management Co., Ltd. |
| 18019033 | FILM-COATED TABLET | Final Rejection | SHANGHAI SUNTECH PHARMACEUTICAL CO., LTD. |
| 17760000 | Protection From Ionizing Radiation | Final Rejection | Avisa Myko, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy